RiDYMO® Designs Cyclic Peptide for “Undruggable” β-Catenin Target Within Two Months 
Repligen to Report First Quarter 2021 Financial Results
Webcast and Conference Call to Be Held Tuesday, May 4, 2021 at 8:30 a.m. EDTWALTHAM, Mass., April 20, 2021 (GLOBE...
Skylight Health Group Announces Fourth Quarter and Full-Year 2020 Results
Full-Year Revenues $13.1 million; Fourth Quarter Revenues rose to $3.2 million; Full Year 2021 Revenue Guidance $40 million; Acquired Six Primary Care Practices...
THC Therapeutics Has Completed the dHydronator® Consumer Model Design with photos
dHydronator® lineup. A lineup of the various potential trims options or colors for the finalized consumer model design of the...
Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001™ in Sickle Cell Disease and Beta Thalassemia
- Under terms of amended agreement, Vertex to lead worldwide development, manufacturing and commercialization of CTX001- - Revised agreement provides...
PharmaTher Announces Submission of IND Application with the FDA for Phase 2 Clinical Trial Evaluating Ketamine in the Treatment of Parkinson’s Disease
TORONTO, April 20, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (CSE: PHRM) (OTCQB: PHRRF), a specialty...
KidneyIntelX Demonstrates Performance and Informs Treatment Decisions in Multinational CANagliflozin CardioVAScular Assessment Study (CANVAS)
Data from 1,325 CANVAS Participants with Baseline DKD Scored with KidneyIntelX Presented at International Society of Nephrology World Congress of...
Autolus Therapeutics Receives Innovation Passport and entry into ILAP for AUTO4 for the treatment of T cell receptor constant region beta chain 1 (TRBC1) positive T cell lymphomas
LONDON, April 20, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell...
CareDx Showcases Transplantation Innovation and Leadership in Europe at EFI 2021
Virtual Events to Highlight New Data and AlloSeq Solutions for European Labs and CliniciansSOUTH SAN FRANCISCO, Calif., April 20, 2021...
Intra-Cellular Therapies Announces Board of Director Nominations in Advance of 2021 Annual Meeting
Board of Directors Nominates Sir Michael Rawlins GBE M.D., FRCP, FMedSci, Former Chairman of the UK’s Medicines and Healthcare products...
Cambium Networks Corporation Announces First Quarter 2021 Reporting Date
ROLLING MEADOWS, Ill., April 20, 2021 (GLOBE NEWSWIRE) -- Cambium Networks Corporation (“Cambium Networks”) (NASDAQ: CMBM), a leading provider of...
Cyclerion Therapeutics to Host Pipeline Update Webinar
Company to discuss clinical updates for CY6463, including Phase 2a studies in ADv and MELAS, and plans to initiate Phase...
ProQR Announces Annual Meeting of Shareholders
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company...
SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics
SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics Adds unique gene-independent approach to treat the later stages...
Acarix publishes the annual report for 2020
Press releaseMalmö, Sweden, April 20, 2021 Acarix publishes the annual report for 2020 Today, Tuesday April 20, Acarix is...
Leading BioSciences Announces Early Efficacy Signal in Reducing Post-Surgical Adhesions in Open Label Study
CARLSBAD, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- Leading BioSciences, Inc. (“LBS” or "the Company"), a privately held company that...
Silo Wellness Appoints Phytomedicine Business Leader as Board Member
TORONTO, April 20, 2021 (GLOBE NEWSWIRE) -- Silo Wellness Inc. (CSE: SILO) (FRA:3K70), a wellness company in the psychedelics and...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2021
Company Announcement Net sales of DARZALEX® in the first quarter of 2021 totaled USD 1,365 millionGenmab receives royalties on worldwide...
GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex
– Tuberous sclerosis complex (TSC) represents a third indication for GW’s cannabidiol in Europe – – TSC causes epilepsy in...
Embark Delta Inc. Completes New Product Shipment to Province of British Columbia
Toronto, Ontario--(Newsfile Corp. - April 20, 2021) - Embark Delta Inc., a wholly owned subsidiary of Embark Health Inc. ("Embark"...
LivaNova Receives FDA 510(k) Clearance for B-Capta, the New In-Line, Blood-Gas Monitoring System Integrated Into the S5 Heart-Lung Machine
Intuitive, optical-based technology system now available around the world LONDON--(BUSINESS WIRE)--#510k--LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company,...